Halozyme Therapeutics, Inc.HALONASDAQ
Loading
R&D Expense Growth AcceleratingAccelerating
Percentile Rank100
3Y CAGR+34.3%
Year-over-Year Change
Year-over-year research & development expense growth
3Y CAGR
+34.3%/yr
Quarterly compound
Percentile
P100
Near historical high
vs 3Y Ago
2.4x
Strong expansion
Streak
1 qtr
Consecutive growthAccelerating
| Period | Value |
|---|---|
| Q4 2025 | 84.90% |
| Q3 2025 | -1.66% |
| Q2 2025 | 18.54% |
| Q1 2025 | -27.60% |
| Q4 2024 | 10.74% |
| Q3 2024 | -12.26% |
| Q2 2024 | 10.08% |
| Q1 2024 | -10.43% |
| Q4 2023 | 23.18% |
| Q3 2023 | -12.20% |
| Q2 2023 | 9.72% |
| Q1 2023 | -20.33% |
| Q4 2022 | 35.09% |
| Q3 2022 | 7.89% |
| Q2 2022 | 30.63% |
| Q1 2022 | 17.26% |
| Q4 2021 | 19.11% |
| Q3 2021 | 5.17% |
| Q2 2021 | -10.43% |
| Q1 2021 | 22.07% |
| Q4 2020 | -4.74% |
| Q3 2020 | -13.45% |
| Q2 2020 | -11.88% |
| Q1 2020 | -77.48% |
| Q4 2019 | 48.12% |
| Q3 2019 | -10.19% |
| Q2 2019 | 8.24% |
| Q1 2019 | -14.52% |
| Q4 2018 | 3.12% |
| Q3 2018 | -11.34% |
| Q2 2018 | 5.56% |
| Q1 2018 | -8.22% |
| Q4 2017 | 21.72% |
| Q3 2017 | -11.34% |
| Q2 2017 | 3.80% |
| Q1 2017 | -10.67% |
| Q4 2016 | 22.11% |
| Q3 2016 | -4.69% |
| Q2 2016 | -11.40% |
| Q1 2016 | 44.53% |